Residual stroke risk despite oral anticoagulation in patients with atrial fibrillation

[1]  S. Yusuf,et al.  Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke. , 2021, The New England journal of medicine.

[2]  Pamela J. McCabe,et al.  Adherence to Guideline-Directed Stroke Prevention Therapy for Atrial Fibrillation Is Achievable: First Results From Get With The Guidelines–Atrial Fibrillation (GWTG-AFIB) , 2019, Circulation.

[3]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association , 2019, Circulation.

[4]  V. Salomaa,et al.  Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe) , 2017, Circulation.

[5]  J. Weitz,et al.  Factors XI and XII as Targets for New Anticoagulants , 2017, Front. Med..

[6]  M. Link,et al.  Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48) , 2017, Circulation. Arrhythmia and electrophysiology.

[7]  B. Freedman,et al.  Residual Risk of Stroke and Death in Anticoagulant-Treated Patients With Atrial Fibrillation. , 2016, JAMA cardiology.

[8]  G. Breithardt,et al.  Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial , 2014, European heart journal.

[9]  G. Fonarow,et al.  Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. , 2014, American heart journal.

[10]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[11]  B. Gersh,et al.  Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. , 2013, European heart journal.

[12]  G. Naccarelli,et al.  CHADS2 and CHA2DS2-VASc risk factors to predict first cardiovascular hospitalization among atrial fibrillation/atrial flutter patients. , 2012, The American journal of cardiology.

[13]  B. Gersh,et al.  Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. , 2011, American heart journal.

[14]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[15]  A. Niessner.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[16]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[17]  D. S. Houston,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[18]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[19]  J. Slattery,et al.  Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project) , 1992, BMJ.